---

Transaction Summary

• Completed a $100M IPO in 2014
• Lead product, abicipar, started pivotal Phase III clinical trials for AMD - leading cause of blindness

• Zurich-Schlieren, Switzerland
• SIX: MOLN


• Contact:
  Petri Vainio
  
• www.molecularpartners.com
• IPO

Related News

• Molecular Partners Reveals Programs in Immuno-Oncology
• Molecular Partners selected as Technology Pioneer 2011 by the World Economic Forum
• Allergan and Molecular Partners Announce Acceptance of U.S. FDA Biologics License Application and
• Molecular Partners Received a European Small and Mid-Cap Award